Using antibodies to understand the re-writing of therapeutic paradigms
I would welcome a discussion on off the shelf allo versus “shallow”-geneic, as in my Letter to Shareholders; https://investor.lineagecell.com/news-releases/news-release-details/lineage-cell-therapeutics-issues-letter-stockholders. Bculley@lineagecell.com
Very interesting, thanks for the write-up!
I would welcome a discussion on off the shelf allo versus “shallow”-geneic, as in my Letter to Shareholders; https://investor.lineagecell.com/news-releases/news-release-details/lineage-cell-therapeutics-issues-letter-stockholders. Bculley@lineagecell.com
Very interesting, thanks for the write-up!